

NATURAL ANTICOAGULANT AND ANTI-FIBRINOLYSIS IN PATIENTS WITH CHRONIC RENAL FAILURE WITH AND WITHOUT HEMODIALYSIS

THESIS

*Submitted for the Partial Fulfilment of
M.D. Degree In
(Biochemistry)*

By

AMANY SALAH ELDIN EL WAKKAD
M.B., B.Ch., M.Sc. (Ain Shams)

Supervisors

Prof. Dr. SALAH ELDIN ZAKI EID
*Professor of Biochemistry.
Faculty of Medicine, Ain Shams University.*

**Prof. Dr. NAWAL ABDO
ZIADA**

*Professor of Biochemistry.
Faculty of Medicine,
Ain Shams University.*

**Prof. Dr. WAHID
MOHAMED EL SAID**

*Professor of Int. Med. & Nephrology.
Faculty of Medicine,
Ain Shams University.*

**Prof. Dr. RAFFAT AWAD
ALLAH**

*Professor of Biochemistry.
Basic Medical Science Department,
National Research Center.*

**Prof. Dr. HANNAA EL
TAYEB NASSER**

*Assistant Professor of Biochemistry.
Faculty of Medicine,
Ain Shams University.*

**Biochemistry Department
Faculty of Medicine
Ain Shams University
1996**



اللَّهُ الرَّحْمَنُ الرَّحِيمُ

(قَالُوا سُبْحَنَكَ لَا عِلْمَ لَنَا إِلَّا مَا
عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ)
صَدَقَ اللَّهُ الْعَظِيمُ
سُورَةُ الْبَقَرَةِ (الآيَةُ ٢٢)

ACKNOWLEDGEMENT

*First and foremost, thanks are due to **GOD** for all the blessings with which are endowed.*

*I am greatly honoured to express my profound gratitude to **Prof. Dr. SALAH ELDIN ZAKI EID**, Professor of Biochemistry, Faculty of Medicine, Ain Shams University, for suggesting the subject of this work, for providing the facilities to carry out this work and for his enthusiastic supervision and encouragement throughout the whole course of this study.*

*My deep appreciation and thanks to **Prof. Dr. NAWAL ABDO ZIADA**, Professor of Biochemistry, Faculty of Medicine, Ain Shams University, for her valuable scientific advices and for whom no words of gratitude are sufficient.*

*I would like to express my deepest thanks to **Prof. Dr. WAHID MOHAMED EL SAID**, Professor of Internal Medicine & Nephrology, Faculty of Medicine, Ain Shams University, for his great help in selecting and supplying the material of this work and for his continuous guidance in the clinical part of my study.*

*My deep appreciation and thanks to **Prof. Dr. RAFFAT AWAD ALLAH**, Professor of Biochemistry, Basic Medical Science Department, National Research Centre, Dokki, Cairo, for his valuable scientific advices and guidance.*

*I am indeed thankful to **Dr. HANNAA EL TAYEB NASER**, Assistant Professor of Biochemistry, Faculty of Medicine, Ain Shams University, who gave me most of her time helping in carrying out the practical work and revising the manuscript. Her friendly and scientific advice and her enthusiastic help are beyond acknowledgement.*

*I would like to express my sincere gratitude and deep appreciation to **Dr. ZAKARIA EL KHIAT**, Lecturer of Biochemistry, Basic Medical Science Department, National Research Centre, Dokki, Cairo, for his great help.*

Also, I would like to thank deeply all the members of Biochemistry Department, Faculty of Medicine, Ain Shams University, for their great friendship, help and encouragement throughout the whole work.

CONTENTS

	<i>Page</i>
LIST OF TABLES	i
LIST OF FIGURES	vi
LIST OF ABBREVIATIONS	viii
INTRODUCTION AND AIM OF THE WORK	1
REVIEW OF LITERATURE	4
BLOOD CLOTTING	18
PLASMA PROTEASE INHIBITORS	36
MATERIALS AND METHODS	46
RESULTS	67
DISCUSSION	125
SUMMARY	142
ABSTRACT	145
REFERENCES	146
ARABIC SUMMARY .	

LIST OF TABLES

- Table (1)** : Depicted the clotting time for normal control group assayed by timing clot formation in one-stage, coagulation assay with plasma deficient in factors II, V, VIII, X.
- Table (2)** : Shows the clotting time for patients group without hemodialysis (conservative treatment) assayed by timing clot formation in one-stage, coagulation assay with plasma deficient in factors II, V, VIII, X.
- Table (3)** : Shows the clotting time for patients group subjected for hemodialysis twice weekly assayed by timing clot formation in one stage, coagulation assay with plasma deficient in factors II, V, VIII, X.
- Table (4)** : Shows the clotting time for patients group subjected for hemodialysis thrice weekly assayed by timing clot formation in one stage, coagulation assay with plasma deficient in factors II, V, VIII, X.
- Table (5)** : Is a comparison table for clotting time assayed by timing clot formation in one stage, by plasma deficient in factors II, V, VIII, X, between the normal group, the conservative treatment group, the twice weekly hemodialysed group and the thrice weekly hemodialysed group.
- Table (6)** : Represents the probability relation of factor II for the normal, conservative treatment, twice/week hemodialysed, thrice/week hemodialysed groups.
- Table (7)** : Represents the probability relation of factor V for the normal, conservative treatment, twice/week hemodialysed, thrice/week hemodialysed groups.
- Table (8)** : Represents the probability relation of factor VIII for the normal, conservative treatment, twice/week hemodialysed, thrice/week hemodialysed groups.

- Table (9)** : Represents the probability relation of factor X for the normal, conservative treatment, twice/week hemodialysed, thrice/week hemodialysed groups.
- Table (10)** : Represents the standard curve for antithrombin III activity assay showing the percentage of activity and their corresponding absorbance values.
- Table (11)** : Shows the activity of antithrombin III in percentage of normal for normal control group.
- Table (12)** : Shows the activity of antithrombin III in percentage of normal for patients group without hemodialysis (conservative treatment).
- Table (13)** : Represents the activity of antithrombin III in percentage of normal for patients subjected for hemodialysis twice/week.
- Table (14)** : Represents the activity of antithrombin III in percentage of normal for patients subjected for hemodialysis thrice/week.
- Table (15)** : Comparison table for activity of antithrombin III in percentage of normal between the normal control group, patients without hemodialysis (conservative treatment group), the twice/week hemodialysed patients group and the thrice/week hemodialysed patients group.
- Table (16)** : Represents the probability relation of antithrombin III for the normal control group, conservative treatment group, twice/week hemodialysed group and the thrice/week hemodialysed group.
- Table (17)** : Represents the standard curve for protein C activity assay showing the percentage of activity and their corresponding absorbance values.
- Table (18)** : Represents the activity of protein C in percentage of normal for normal control group.

- Table (19)** : Represents the activity of protein C in percentage of normal for conservative treatment group.
- Table (20)** : Represents the activity of protein C in percentage of normal for patients subjected for hemodialysis twice/week.
- Table (21)** : Represents the activity of protein C in percentage of normal for patients subjected for hemodialysis thrice/week.
- Table (22)** : Comparison table for protein C activity represented as percentage of normal between the normal control group, the conservative treatment group, the twice/week hemodialysed group and the thrice/week hemodialysed group.
- Table (23)** : Represents the probability relation of protein C activity for the normal, conservative treatment, twice/week hemodialysed group and thrice/week hemodialysed group.
- Table (24)** : Represents the calibrators for the total protein S assay showing the percentage level of concentration and their corresponding absorbance values.
- Table (25)** : Represents total protein S level of concentration for the normal control group.
- Table (26)** : Represents total protein S level of concentration for the conservative treatment group.
- Table (27)** : Represents total protein S level of concentration for the twice/week hemodialysed group.
- Table (28)** : Represents total protein S level of concentration for the thrice/week hemodialysed group.
- Table (29)** : Comparison table for protein S level of concentration between normal control group and conservative treatment, twice/week hemodialysed and thrice/week hemodialysed group.

- Table (30)** : Represents the probability relation of protein S level of concentration for the normal, conservative treatment, twice/week hemodialysed group and thrice/week hemodialysed group.
- Table (31)** : Represents the α_1 -antitrypsin concentration in percentage of normal for normal control group.
- Table (32)** : Represents the α_1 -antitrypsin concentration in percentage of normal for conservative treatment group.
- Table (33)** : Represents the α_1 -antitrypsin concentration in percentage of normal for patients subjected to hemodialysis twice/week.
- Table (34)** : Represents the α_1 -antitrypsin concentration in percentage of normal for patients subjected to hemodialysis thrice/week.
- Table (35)** : Comparison table for concentration of α_1 -antitrypsin in percentage of normal between the normal control group, the conservative treatment group, twice/week hemodialysed group and the thrice/week hemodialysed group.
- Table (36)** : Represents the probability relation of α_1 -antitrypsin concentration for normal control group, conservative treatment group, twice/week hemodialysed group and the thrice/week hemodialysed group.
- Table (37)** : Represents the α_2 -macroglobulin concentration in percentage of normal for normal control group.
- Table (38)** : Represents the α_2 -macroglobulin concentration in percentage of normal for conservative treatment group.

- Table (39)** : Represents the α_2 -macroglobulin concentration in percentage of normal for patients subjected for hemodialysis twice/week.
- Table (40)** : Represents the α_2 -macroglobulin concentration in percentage of normal for patients subjected for hemodialysis thrice/week.
- Table (41)** : Comparison table for α_2 -macroglobulin concentration in percentage of normal between the normal control group, the conservative treatment group, the twice/week hemodialysed group and the thrice/week hemodialysed group.
- Table (42)** : Represents the probability relation of α_2 -macroglobulin concentration between the normal control group, the conservative treatment group, the twice/week hemodialysed group and the thrice/week hemodialysed group.
- Table (43)** : Summarizes our results by comparing the results of the three groups to the normal group.

